Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial

English
Body: 

Background:

Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recommended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients with COVID-19.

Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study

English
Body: 

In the present prospective, randomized, controlled, and open-label study, a daily dose of 1000 mg of QP was investigated for 30 days in 152 COVID-19 outpatients to disclose its adjuvant effect in treating the early symptoms and in preventing the severe outcomes of the disease. Results: The results revealed a reduction in frequency and length of hospitalization, in need of non-invasive oxygen therapy, in progression to intensive care units and in number of deaths. The results also confirmed the very high safety profile of quercetin and suggested possible anti-fatigue and pro-appetite properties. Conclusion: QP is a safe agent and in combination with standard care, when used in early stage of viral infection, could aid in improving the early symptoms and help in preventing the severity of COVID-19 disease. It is suggested that a double-blind, placebo-controlled study should be urgently carried out to confirm the results of our study. 

Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

English
Body: 

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins were measured in longitudinal plasma samples collected from 13 participants who received two doses of mRNA-1273 vaccine. Eleven of 13 participants showed detectable levels of SARS-CoV-2 protein as early as day 1 after first vaccine injection. Clearance of detectable SARS-CoV-2 protein correlated with production of immunoglobulin G (IgG) and immunoglobulin A (IgA).

Carrageenan nasal spray may double the rate of recovery from coronavirus and influenza virus infections: Re-analysis of randomized trial data

English
Body: 

In this individual patient data meta-analysis we examined datasets of two randomized placebo-controlled trials which investigated the effect of nasal carrageenan separately on children and adults. In both trials, iota-carrageenan was administered nasally three times per day for 7 days for patients with the common cold and follow-up lasted for 21 days. We used Cox regression to estimate the effect of carrageenan on recovery rate. We also used quantile regression to calculate the effect of carrageenan on colds of differing lengths. Nasal carrageenan increased the recovery rate from all colds by 54% (95% CI 15%–105%; p = .003). The increase in recovery rate was 139% for coronavirus infections, 119% for influenza A infections, and 70% for rhinovirus infections. The mean duration of all colds in the placebo groups of the first four quintiles were 4.0, 6.8, 8.8, and 13.7 days, respectively. The fifth quintile contained patients with censored data. The 13.7-day colds were shortened by 3.8 days (28% reduction), and 8.8-day colds by 1.3 days (15% reduction). Carrageenan had no meaningful effect on shorter colds. In the placebo group, 21 patients had colds lasting over 20 days, compared with six patients in the carrageenan group, which corresponds to a 71% (p = .003) reduction in the risk of longer colds. Given that carrageenan has an effect on diverse virus groups, and effects at the clinical level on two old coronaviruses, it seems plausible that carrageenan may have an effect on COVID-19. Further research on nasal iota-carrageenan is warranted.

IS THERE A COVID VACCINE / CANCER CONNECTION?

IS THERE A COVID VACCINE / CANCER CONNECTION?

Multiple sources in The HighWire’s network of Frontline Physicians, have reported an alarming uptick in aggressive cancers post-Covid vaccination. Could there be a link? Pathologist Ryan Cole, MD, discusses the available science and his lab’s findings.

#DrRyanCole #AmericasFrontLineDoctors #mRNAVaccine #VaccineInjury #TheHighwire #DelBigtree #HW234

POSTED: September 24, 2021

https://thehighwire.com/videos/is-there-a-covid-vaccine-cancer-connection/?fbclid=IwAR2_vntfROlZ-RxomeqxL79hSCK0BcD7tzfct-6GHlOmAHnisedLJ_d12NY

Covid 19 early treatment: real time analysis of 977 studies

English
Body: 

This is a very interesting document comparing all tested early treatments against Covid 19 infection.

Avoid Dental Problems With Diet with Dentist Marc DiNola

Undefined
Body: 

" Is sugar the main culprit for dental decay and other issues? Dentist Marc DiNola suggests that a host of dental problems could be caused by nutritional deficiencies. He offers advice for what foods to eat to rectify the situation — including Gouda cheese, organ meats, and fat from pastured animals. He explains how foods rich in vitamin K can keep teeth strong with the proper fluid flow."

PARENT GIVES FACTS TO THE VANDALIA SCHOOL BOARD IN ILLINOIS



mask mandates on the children in schools without considering our freedoms in America or the fact that medical procedures without informed consent is against the Nuremberg Code. I wish every parent was as informed and fiery as she is!

Measles trial, control experiments and the final exposure of corona"virus" farce

https://odysee.com/@katie.su:7/kateinterviewsstefan2:4

( approx. 59 min)
 

Interview with Stefan Lanka, a microbiologist and “virologist” Topics discussed:

-Refutation of the idea of the existence of the measles virus - Stefan’s victory in the measles trial
-Control experiments for the sars-cov-2 virus
-The final exposure of the corona”virus” farce

 

 

 

COVID-19 VACCINE INGREDIENTS

Undefined
Body: 

On 20 August 2021 Dr. Robert Young published his team’s findings after analysing the four dominant COVID-19 “vaccines” using Phase Contrast MicroscopyTransmission and Scanning Electron Microscopy and Energy-Dispersive X-ray Spectroscopy. Their findings both confirm and expand upon the prior investigations carried out by Dr. Pablo Campra (University of Almeria, Spain) and Dr. Juan F. Gastón Añaños (Hospital de Barbastro, Spain). These findings are summarised in the table below.

Many of these substances were observed as being bonded to graphene oxide nanoparticles. GO nanoparticles are necrotic, able to pass into or through physiological barriers including (but not limited to) the blood-air barrier, the blood-testis barrier, the blood-brain barrier, and the blood-placenta barrier. Over a period of several months after intramuscular injection, as much as 75% of the GO nanoparticle “delivery platform”, and most of the substances listed below, are transported extensively throughout the bodies of mammals, into the blood, brain and other organs. Some of the many toxic effects of graphene oxide are myocarditis and blood clotting.

Dr. Andrew Kaufman Panopticon ~ July 10, 2021



 

 

Stefan Lanka: "Viruses are not microbes and have no infectious capacity" (III of III) - DSalud

Undefined
Body: 

The well-known German virologist Stefan Lanka asserts that viruses are neither microbes nor do they have infectious capacity, so that Covid-19 cannot have been caused by the alleged SARS-CoV-2, whose existence, moreover, has not been demonstrated.
Furthermore he disputes that there is a pandemic, that there are millions of people infected and killed by this coronavirus, and that vaccines are justified since they are neither effective nor innocuous but very dangerous.
This is what he affirmed - among many other things - during the extensive interview we had with him in which he reveals the farce that the world is living through due to the constant lies and manipulations of the World Health Organisation (WHO) and the international drug agencies in complicity with the political leaders of most governments.

How Remdesivir/Ventilators Were Used To Murder & Create Illusion of Deadly Virus

https://odysee.com/@Fingerbob:c/21293_480p:6

( approx 11 min.)

 

Dr. Bryan Ardis exposes Hospitals as MURDER ZONES and to never go into one if you have Covid-19. He says "You're going to be threatened with DEATH" if you go into a hospital with Covid-19.

Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance—Nine States, June–August 2021

English
Body: 

Data on COVID-19 vaccine effectiveness (VE) since the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, became the predominant circulating strain in the United States are limited (13). CDC used the VISION Network* to examine medical encounters (32,867) from 187 hospitals and 221 emergency departments (EDs) and urgent care (UC) clinics across nine states during June–August 2021, beginning on the date the Delta variant accounted for >50% of sequenced isolates in each medical facility’s state. VISION Network methods have been published (4).

Eligible medical encounters were defined as those among adults aged ≥18 years who had received SARS-CoV-2 molecular testing (primarily reverse transcription–polymerase chain reaction assay within 14 days before or 72 hours after the admission or encounter) and a COVID-19–like illness discharge diagnosis. Vaccination status was documented in electronic health records and immunization registries. Full vaccination was defined as receipt of the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) mRNA vaccines, or a single dose of Ad26.COV2 (Janssen [Johnson & Johnson]) vaccine ≥14-days before the testing or encounter date. Patients who had received no COVID-19 vaccine doses were considered unvaccinated. Patients who had received 1 mRNA dose only or had received the second dose <14 days before testing or encounter date were excluded. VE was estimated using a test-negative design, calculating the odds of receiving a positive SARS-CoV-2 test result comparing fully vaccinated and unvaccinated patients (referent group). VE was adjusted for age, geographic region, calendar time (days from January 1 to medical event), and virus circulation, and weighted for inverse propensity to be vaccinated or unvaccinated (calculated separately for each VE model). VE estimates with 95% confidence intervals (CIs) that did not overlap were considered statistically different. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.

Among fully vaccinated patients, the proportion who had received each vaccine product among hospitalizations and ED/UC encounters, respectively, were Pfizer-BioNTech, 55.3% and 53.6%; Moderna, 38.8% and 36.1%; and Janssen, 6.0% and 10.3%. The median interval from becoming fully vaccinated to the hospital admission or ED/UC encounter, respectively, were 110 and 93 days (Pfizer-BioNTech), 106 and 96 days (Moderna), and 94 and 94 days (Janssen).

Among adults hospitalized with COVID-19–like illness (14,636; median patient age = 65 years, interquartile range [IQR] = 48–77 years), laboratory-confirmed SARS-CoV-2 infections were identified among 18.9% (1,316 of 6,960) of unvaccinated and 3.1% (235 of 7,676) of fully vaccinated patients. Overall, VE against COVID-19 hospitalization was 86% (95% CI = 82%–89%). VE was significantly lower among adults aged ≥75 years (76%) than among those aged 18–74 years (89%) (Table). The difference in VE point estimates between age groups was similar for Pfizer-BioNTech and Moderna vaccines. Across all ages, VE was significantly higher among Moderna vaccine recipients (95%) than among Pfizer-BioNTech (80%) or Janssen (60%) vaccine recipients.

Among adults with ED/UC encounters for COVID-19–like illness (18,231; median patient age = 43 years, IQR = 29–62 years), laboratory-confirmed SARS-CoV-2 infections were identified among 28.9% (3,145 of 10,872) of unvaccinated and 7.0% (512 of 7,359) of fully vaccinated patients. VE against COVID-19 ED/UC encounters was 82% (95% CI = 81%–84%). VE was highest among Moderna vaccine recipients (92%), followed by Pfizer-BioNTech vaccine recipients (77%), and was lowest (65%) for Janssen vaccine recipients (Table).

In this multistate interim analysis of 32,867 medical encounters among adults of all ages during June–August 2021, when the Delta variant was predominant in the United States, VE of all three authorized COVID-19 vaccines combined remained high against hospitalization (86%) and ED/UC encounters (82%). These overall VE estimates were similar to those during the months before Delta became predominant (2,4). However, VE against COVID-19 hospitalization among adults aged ≥75 years was significantly lower than that among adults aged <75 years, which had not been observed previously from this data source (4). This moderate decline should be interpreted with caution and might be related to changes in SARS-CoV-2, waning of vaccine-induced immunity with increased time since vaccination, or a combination of factors. Differences in VE between the two mRNA vaccines, which had not been observed previously in the VISION Network (4), are consistent with another recent finding.§ Further examination of the magnitude and sources of product-specific VE differences are also warranted.

The findings in this report are subject to at least three limitations. First, VE by time since vaccination was not examined; further evaluation of possible waning of vaccine protection is currently underway. Second, VE for partial vaccination was not assessed. Finally, although the facilities in this study serve heterogenous populations in nine states, the findings might not be generalizable to the U.S. population.

These findings reaffirm the high protection of COVID-19 vaccines against moderate and severe COVID-19 resulting in ED, UC, and hospital visits and underscore the importance of full COVID-19 vaccination and continued benefits of COVID-19 vaccination during Delta variant predominance.

Review of Russian ezrin peptide treatment of acute viral respiratory disease and virus induced pneumonia; a potential treatment for covid-19

English
Body: 

2
COVID-19patients display a spectrum of disease severity.
About 80% haveAcute Viral Respiratory Disease (AVRI) withfever

A dialogue about injection safety and efficacy between Pastor Askofu Gwajima and Dr. Mike Yeadon.

 

This is an extract from our previous video, where the main religious leader of Tanzania, with 2.9 million followers and 400 churches, Pastor Askofu Gwajima invited the Tanzanian government on a debate on safety and efficacy about the Covid injections. The government did not show up, but Pastor Gwajima had a very intesting with the vaccine expert Dr. Mike Yeadon, former vice President of Pfizer.

Pages

Subscribe to Medic Debate RSS